Discovery of a novel RSK2 inhibitor for the treatment of metastatic pancreatic cancer.

J Enzyme Inhib Med Chem · 2025 · PMC12326382 · PMID 40762406

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

did not reach statistical significanceno p-value reported

While the GEPIA2-based survival analysis using a median cut-off did not reach statistical significance, a trend towards poorer survival in the RSK2-high group was observed.

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.